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Abstract
Streptococcus pyogenes (group A streptococcus, GAS) is a Gram-positive bacterial pathogen responsible for a wide variety of
diseases. To date, GAS vaccine development has focused primarily on the M-protein. The M-protein is highly variable at the
amino (N)-terminus (determining serotype) but is conserved at the carboxyl (C)-terminus. Previously a 29 amino acid
peptide (named J14) from the conserved region of the M-protein was identified as a potential vaccine candidate. J14 was
capable of eliciting protective antibodies that recognized many GAS serotypes when co-administered with immuno-
stimulants. This minimal epitope however showed no immunogenicity when administered alone. In an attempt overcome
this immunological non-responsiveness, we developed a self-adjuvanting vaccine candidate composed of three
components: the B-cell epitope (J14), a universal helper T-cell epitope (P25) and a lipid moiety consisting of lipoamino
acids (Laas) which target Toll-like receptor 2 (TLR2). Immunological evaluation in B10.BR (H-2k) mice demonstrated that the
epitope attachment to the point of lipid moiety, and the length of the Laa alkyl chain have a profound effect on vaccine
immunogenicity after intranasal administration. It was demonstrated that a vaccine featuring C-terminal lipid moiety
containing alkyl chains of 16 carbons, with P25 located at the N-terminus, and J14 attached to the side chain of a central
lysine residue was capable of inducing optimal antibody response. These findings have considerable relevance to the
development of a broad spectrum J14-based GAS vaccine and in particular provided a rational basis for peptide vaccine
design based on this self-adjuvanting lipopeptide technology.
Citation: Zaman M, Abdel-Aal A-BM, Fujita Y, Phillipps KSM, Batzloff MR, et al. (2012) Immunological Evaluation of Lipopeptide Group A Streptococcus (GAS)
Vaccine: Structure-Activity Relationship. PLoS ONE 7(1): e30146. doi:10.1371/journal.pone.0030146
Editor: Vladimir Brusic, Dana-Farber Cancer Institute, United States of America
Received October 31, 2011; Accepted December 12, 2011; Published January 12, 2012
Copyright:  2012 Zaman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Health and Medical Research Council of Australia (NHMRC Programme Grant 496600). MZ acknowledges the
University of Queensland for the financial support through a Ph.D. funding scholarship. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: i.toth@uq.edu.au
Introduction
Group A streptococcus (Streptococcus pyogenes, or GAS) is a Gram-
positive bacteria that causes various diseases ranging from the
relatively benign pharyngitis (‘strep throat’) to more invasive
necrotizing fasciitis [1]. The post-infectious complications arising
from GAS such as rheumatic fever (RF) and rheumatic heart
disease (RHD) are responsible for the greatest health burden by
causing the majority of morbidity and mortality (estimated at 12
million cases annually with 380,000 fatalities) [2–3]. Inadequate or
delayed treatment of GAS infections can result in the development
of these diseases and highlights the need for a protective GAS
vaccine [4].
Development of a vaccine against GAS infections focused on the
M-protein, an abundant cell surface protein. The M-protein is
expressed by all GAS and is a major virulence factor [4]. Protective
immunity against GAS infections has been associated with
antibodies directed against the N-terminal or C-terminal regions
of the M-protein [4,5]. Protected individuals produce systemic IgG
antibodies reactive to M-protein, enhancing phagocytosis and
killing of the bacterium [4,6]. The hypervariability of the N-
terminal region made it difficult to develop a successful global
vaccine for all serotypes of GAS. However an N-terminal based
approach could be well suited for vaccines targeting specific GAS
serotypes in particular geographical locations [7–9]. A vaccine
strategy based on the conserved C-terminal region of the M protein
can overcome these restrictions [4,6,10–13].
We have previously identified a peptide named J14
(KQAEDKVKASREAKKQVEKALEQLEDKVK) containing
14 amino acids from the conserved GAS M-protein C region
(shown in bold) enclosed within non-streptococal peptide sequenc-
es, designed to retain the native alpha-helical structure [14,4]. This
propensity to form a helix was critical for functionality as the
immunodominant epitope displayed within J14 is alpha-helical in
conformation [15].
Short synthetic peptides such as J14 are not sufficiently
immunogenic on their own necessitating the use of adjuvant [4].
Bacterial lipoproteins/lipopeptides have been shown to enhance
immune responses to otherwise weak immunogens comparable to
the classical oil in water emulsion generated using Freund’s
complete adjuvant (CFA) [16]. Chemical conjugation of synthetic
(including lipoamino acids or Laa, Figure 1) or bacterial derived
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or no side effects [16–20].
The potent adjuvant activity of these lipopeptides was due to the
recognition of the lipid tail by the pathogen recognition receptor
Toll-like receptor-2 (TLR2) [18,19].
To elicit antibodies against J14 without use of toxic adjuvants,
we developed fully synthetic self-adjuvanting vaccine constructs
(Figure 2a), composed of (i) a universal helper T-cell epitope (P25),
(ii) the target GAS B-cell epitope (J14), and (iii) a lipid moiety
based on Laa targeting TLR2. Since we are using racemic Laa,
diasteromeric lipopeptides were utilized in the current study. The
T-helper cell epitope (P25) was used to generate the proliferation
of T cells to deliver help for antibody responses.
Varying the position of epitopes (J14 and P25) and the lipid
moiety significantly affected the systemic J14-specific IgG response
following intranasal administration (Lipopeptides 1-5, Figure 2a–
c). In order to optimize the adjuvanting activity of the lipid moiety,
the effect of alterations in the length of Laa was also investigated
(Figure 2a). The J14 and P25 peptides were also incorporated into
a lipid core peptide (LCP) system (Figure 2d).
Materials and Methods
I. Lipopeptide synthesis
All constructs (Figure 2a-d) were synthesized using standard
BOC chemistry [21]. Synthesis and physiochemical characteriza-
tion of lipopeptides and LCP was previously described in detail
elsewhere [21]. Briefly, for synthesis of lipopeptide 1, two cycles of
racemic Boc-protected C16 Laa was coupled to the resin, followed
by two cycles of Boc-Ser(Bzl)-OH, and one Boc-Lys(Fmoc)-OH
residue. Following Boc-deprotection of the lysine a-amine, the P25
peptide (sequence, KLIPNASLIENCTKAEL) was synthesized
followed by N-terminal amine acetylation. The central lysine
epsilon (e) -Fmoc group was then removed, followed by the
synthesis of the J14 sequence. For synthesis of diasteromeric
lipopeptide 2-3, two cycles of the appropriate Boc-protected Laa
were coupled to the resin followed by the same synthesis procedure
as lipopeptide 1 for attaching P25 and J14. For lipopeptides 4-5,
P25 was synthesized either N or C-terminally to J14. In both cases,
Boc-protected C16 Laa was attached to the e-amino group of the
intervening lysine residue placed between the 2 epitopes.
II. Intranasal immunization
Four to six week old female B10.BR mice (Animal Resource
Centre, Perth, Western Australia) were intranasally immunized
with 60 mg of diastereomeric lipopeptides 1-5 and diastereomeric
LCP dissolved in 30 mL (15 mL/nare) of phosphate-buffered saline
(PBS), followed by similar booster doses on days 21 and 41 post-
primary immunization. Mice to be immunized were anesthetized
first with a mixture of xylazine and ketamine (1:1:10 mixture of
xylazine:ketamine:H2O; Provet, Brisbane, Australia). The positive
control received 30 mg of J14 conjugated to the carrier protein
Diptheria toxoid (DT) emulsified in a total volume of 50 mLo f
CFA subcutaneously at the tail base (J14-DT/CFA). Negative
controls were given 50 mL of either PBS alone or 30 mgo fD Ti na
Figure 1. The structure of lipoamino acid (Laa). Lipoamino acids
are described according to the total number of carbon atoms in the
molecule. C12 Laa; n=9. C14 Laa; n=11. C16 Laa; n=13.
doi:10.1371/journal.pone.0030146.g001
Figure 2. Structure of the lipopeptide vaccine candidates grouped according to the orientation of epitopes and Laa in the current
study. * Lipopeptide 1 (C16 Laa), Lipopeptide 2 (C14 Laa), Lipopeptide 3 (C12 Laa).
doi:10.1371/journal.pone.0030146.g002
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Negative controls were boosted with 50 mL of PBS and the positive
control was boosted with 30 mg of J14 in a total volume of 50 mL
of PBS. All animal protocols used were approved by the Institute’s
ethics committee (Griffith University Research Ethics Review
Board for Animal-Based Work, GU Ref No: BDD-06-10-AEC) in
accordance with National Health and Medical Research Council
(NHMRC) of Australia guidelines.
III. Collection of serum
Serum was collected on days 20, 40 and 60 post-primary
immunization to determine the level of J14-specific systemic
antibodies. Blood was collected from mice via the tail artery and
allowed to clot for at least 30min at 37uC. Serum was collected
after centrifugation for 10 min at 1000 g, heat inactivated for 10
min at 56uC and stored at 220uC.
IV. Determination of antibody titers by ELISA
An enzyme linked immunosorbent assay (ELISA) was used to
measure J14-specific serum IgG titers as described elsewhere [21].
Tested lipopeptides were compared to the LCP analogue, PBS
administered intranasally and to J14-DT/CFA and DT/CFA
administered subcutaneously. The titer was described as the lowest
dilution that gave an absorbance of .3 standard deviation (SD)
above the mean absorbance of control wells (containing normal
mouse serum immunized with PBS). Statistical significance
(p,0.05) was determined using a one-way analysis of variance
(ANOVA) with Tukey post hoc test.
For the IgG subtype determination, mice sera from each group
was pooled together and ELISA was done for the four antibody
isotypes in duplicates for each group. Horse radish peroxidase-
conjugated sheep anti-mouse IgG1, IgG2a, IgG2b and IgG3
antibodies were used as the secondary antibodies.
V. Cell culture
Human embryonic kidney (HEK293) cells were cultured at 37
uCi n5 %C O 2 in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% heat-inactivated serum supreme (BioWhittaker,
Maryland, United States of America), 2 mM L-glutamine (L-Gln),
1 mM sodium pyruvate, and 500 mg/ml G418 sulfate (Geneticin).
Cells were maintained in BD Falcon
TM 75 cm
2 cell culture flask
and passaged every 3–4 days. The HEK293 cells were a gift from
Dr. Ashley Mansell, Monash Institute of Reproduction and
Development, Victoria, Australia.
VI. HEK293 cell transfection and stimulation
HEK293 cells stably expressing TLR2 was assayed for their
responsiveness to lipopeptides 1-3 and 5. HEK293 cells were
transfected with 1 mgo fp N F kB-Luc Cis-Reporter plasmid per
1610
6 cells. pNFkB-Luc encodes firefly luciferase as a reporter gene
for activation of the transcription factor NFkB. Consequently,
increased luciferase activity in transfected HEK293 cells was directly
proportional to the TLR2 mediated NFkB activation. Medium was
changed to OPTI-MEMI medium (Invitrogen, California, United
States of America) just before transfection and the transfection
mixture was made by diluting 150 ml of 1,2-Dioleoyloxy-3-
trimethylammoniumpropane chloride (DOTAP chloride) and L-
alpha dioleoyl phosphatidyl ethanolamine (DOPE) in a 1:1 ratio in
150 ml of OPTI-MEMI medium. 6 mg of plasmid DNA in 134.4 ml
of OPTI-MEMI was then added to the transfection mixture. After a
10-min incubation at room temperature, the DNA-transfection
mixture was diluted with 2.55 ml of OPTI-MEMI medium to afford
addition of DNA-Lipofectamine mixture at 500 mlp e rw e l l .W h i l s t
only 5 wells were transfected, excess DNA was used to account for
possible loss of DNA or pipetting errors.
After incubation for 24 h at 37uCi n5 %C O 2, the cells were
seeded into 24-well plate (1.5610
5 cells/well) and the medium was
refreshed to DMEM (along with 10% heat-inactivated serum
supreme, 2 mM L-Gln, 1 mM sodium pyruvate) and incubated
overnight. Post transfection (44 hr), triplicate wells were stimulated
with diastereomeric lipopeptides 1-3 and 5 at 200 nM, 1.4 mM
and 10 mM to deduce dose response. As controls, triplicate wells
were stimulated with the TLR2 ligand dipalmitoyl-S-glyceryl
cysteine (Pam2Cys, gift from Dr. Michael Batzloff, Queensland
Institute of Medical Research, Queensland, Australia) at a
concentration of 1.4 mM and medium alone (DMEM, 10%
heat-inactivated serum supreme, 2 mM L-Gln, 1 mM sodium
pyruvate). After 4 hr, cells were lysed and assayed for luciferase
activity. Each experiment was repeated twice.
VII. Luciferase reporter assay for NFkB activity
HEK293 cells were assayed for luciferase activity using the
Dual-Glo luciferase assay kit (Promega, Wisconsin, United States
of America). Cells were washed twice with 100 ml of PBS and lysed
in 100 ml of passive lysis buffer (provided with the kit). The cell
lysate was then centrifuged at 12470 g for 30 seconds at room
temperature, and 10 ml of the supernatant was mixed with 50 mlo f
firefly luciferase substrate (luciferine) in a luminometer plate. The
light illuminated was calculated using an illuminometer (Turner
Designs, California, United States of America). The luciferase
activity of each sample was normalized to the concentration of
solubilized protein via the Bio-Rad Protein Assay (Bio-Rad,
California, United States of America). After addition of the protein
assay dye to 5 ml of lysate supernatant in 200 ml of Milli-Q water,
the differential color change was measured at an absorbance of
595 nm with a Bio-Rad Benchmark Microplate Reader.
Experimental data was shown as the relative increases over those
cells treated with medium only. Data are shown as means 6 SD of
three cultures run in a given experiment. Variation between
Figure 3. J14-specific serum IgG titers (log10) at the final bleed
(day 60) after primary immunization for each individual
mouse. Mean J14-specific IgG antibody titers are represented as a
bar. Statistical analysis was performed using a one-way ANOVA
followed by the Tukey post hoc test (ns, p.0.05; *, p,0.05; **,
p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0030146.g003
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regarded statistically significant if the p value was , 0.05.
Results
1. Antibody response to lipopeptides
Following intranasal immunization, cohorts of mice adminis-
tered lipopeptide 1 were shown to induce the highest J14-specific
systemic IgG titers (Figure 3). These titers were significantly higher
than the mice administered DT/CFA and PBS (Figure 3;
lipopeptide 1 vs DT/CFA and PBS, p,0.001). The higher J14-
specific IgG titers induced by lipopeptide 1 in comparison to the
LCP system and analogues of 1 with shorter Laa alkyl chain length
(Lipopeptides 2, 3) was not statistically significant (Figure 3;
lipopeptide 1 vs LCP and lipopeptides 2-3, p.0.05). Lipopeptide
1 induced comparable IgG titers to mice immunized with J14-
DT/CFA (Figure 3; J14-DT/CFA vs lipopeptide 1, p.0.05).
Taken together, these data suggested that C16 Laa as in
lipopeptide 1 was optimal for immunogenicity.
To investigate the effect of varying epitope and lipid orientation
on J14-specific IgG titers, lipopeptides with the same C16 Laa but
different epitope/lipid positioning were selected for comparison
(Lipopeptides1,4and 5).Thepointoflipidattachment significantly
affected the J14-specific IgG antibody response (Figure 3; lipopep-
tide 1 vs 4-5, p,0.001). Lipopeptide 1 (C16 Laa attached to the C-
terminus) resulted in significantly higher antibody titers than
lipopeptides 4 and 5 (where the lipid moiety was attached to the
side chain e-amine of the central lysine residue).
Lipopeptide 4 in comparison to 5 only differs in the orientation
of the P25 and J14 epitope. The higher antibody titers observed
for lipopeptide 5 in comparison to 4 was not statistically significant
(Figure 3; lipopeptide 5 vs 4, p.0.05)
Figure 4. Isotypes of J14-specific serum IgG titers (log10) present in the final bleed (day 60) after primary immunization. Bars
represent the titer for pooled sera obtained from each group. Error bars represent standard error of mean.
doi:10.1371/journal.pone.0030146.g004
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isotypes were analyzed. The most common IgG isotype observed
for lipopeptides 1-3, 5 and the LCP system was IgG1 (Figure 4a).
Lipopeptide 1 elicited significantly higher IgG1 titers than mice
administered lipopeptide 5 and J14+CFA/DT (Figure 4a; lipo-
peptide 1 vs lipopeptide 5 or J14-CFA/DT, p,0.001). Whilst the
LCP construct elicited the highest IgG1 titre (Figure 4a), it should
be noted that lipopeptide 1 was more immunogenic in view of the
total IgG titre (Figure 3).
Following subcutaneous immunization with the positive control
group J14-CFA/DT, predominantly IgG1 response was observed.
Lower levels of IgG2a and IgG2b and antibodies were also elicited
by J14-CFA/DT (Figure 4a–c).
Lipopeptide 1 in comparison to lipopeptides 2-5 and
J14+CFA/DT elicited higher but not statistically different levels
of IgG2a antibodies (Figure 4b; lipopeptide 1 vs lipopeptides 2-5
and J14-CFA/DT, p.0.05).
Lipopeptide 1 induced significantly higher IgG2b titers in
comparison to mice administered lipopeptides 2, 4-5 and the LCP
analogue (Figure 4c; lipopeptide 1 vs lipopeptides 2, 4-5 and LCP,
p,0.001). Lipopeptide 1 induced IgG2b titers were also
comparable to cohorts of mice administered J14-CFA/DT
(Figure 4c; lipopeptide 1 vs J14-CFA/DT, p.0.05).
The few titers of IgG3 observed for lipopeptide 1 was
comparable to levels of IgG3 titers induced by J14-DT/CFA or
LCP (Figure 4d; lipopeptide 1 vs J14-DT/CFA and LCP, p.0.05).
Overall the IgG isotype data suggested that the trend for the
lipopeptides was to induce preferential switching to IgG1 followed
by IgG2b and IgG2a antibodies (T helper cell type 2 (TH2) biased
response).
Figure 5. The ability of the lipopeptides to signal through TLR2 was tested by using HEK293 cells stably expressing TLR2
transfected with an NFkB-luciferase reporter gene. The several fold increase in NFkB levels in treated cells are shown relative to that of the
TLR2-expressing cells treated with media, which was set to a value of 1. Bars are means 6 SD of indicated number of experiments (ns, p.0.05; *,
p,0.05; ** p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0030146.g005
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Two lipoamino acids provided our lipid moiety with two long
alkyl chains, giving the lipid moiety structural similarity to the
known TLR2 agonist Pam2Cys. Lipopeptide 1 with two copies of
C16 Laa induced significant TLR2 stimulation at 10 mM
concentration in comparison to cells treated with medium
(Figure 5a). Lipopeptides 2-3, which contained shorter alkyl
chains in comparison to lipopeptide 1, failed to induce significant
TLR2 stimulation (Figure 5b, c). Lipopeptide 5 containing the
same alkyl chain length as lipopeptide 1 but differing in position of
the lipid moiety also induced significant TLR2 stimulation at
10 mM (Figure 5d).
Discussion
Signaling through TLRs had been shown to result in robust and
wide-ranging immune responses against peptide epitopes [18].
Our results suggested an alkyl chain length of 16 carbons for the
Laa is optimal for stimulation of TLR2. The two ester bound fatty
acids in Pam2Cys also contain chain length of 16 carbons which
was said to be optimal for immunogenicity and activation of TLR2
[22,23]. Lipopeptide 1 featured Laa with an alkyl chain of 16
carbons which may explain its ability to produce noticeable higher
IgG titers in comparison to lipopeptides with shorter alkyl chain
(Lipopeptides 2-3).
Protection against GAS infection following vaccination is
acquired by elicitation of high level of anti-GAS specific antibodies
[24]. Lipopeptide 1 was shown to elicit comparable level of J14-
specific IgG titers to mice administered J14 conjugated to DT and
co-administered with CFA (a gold standard for adjuvant strength).
Therefore immunization with lipopeptide 1 induced high level of
anti-GAS specific antibodies which could confer protection against
GAS infection. The selective induction of TH1 and TH2 cells can
also mediate the protective immunity against certain diseases [25].
AT H2 response can provide protection against extracellular
infection [26]. Therefore the TH2 biased response observed for
our lipopeptides could be ideal for a protective immune response
against GAS infection.
In the current study it was observed that positioning of the lipid
moiety and peptide epitopes had a significant effect on
immunogenicity. Our observation was that P25 at the N-terminus
with J14 on the side-chain of the central lysine and a C-terminal
lipid moiety with C16 Laa and was optimal for immunogenicity
(lipopeptide 1). The finding that incorporation of the lipid moiety
and epitopes into different position influencing immunogenicity is
in line with previous structure-activity studies [20–21]. Never the
less the structure-activity relationship in the current study is
important for designing successful peptide vaccines administered
intranasally and provides another strategy for lipopeptide vaccine
candidates based on Laa.
As the self-adjuvanting lipopeptides described in this study
eliminated the use of any additional adjuvant and did not require
conjugation to a carrier protein like DT, it can also overcome
problems associated with peptide vaccines, including detrimental
side effects of using more potent adjuvants and epitope suppression
due to presence of antibodies to carrier proteins such as DT [21].
Paritcular features of lipopeptide 1 are also advantageous over
the LCP system and other TLR2 targeting lipopeptides. Lipopep-
tide 1 contained one copy of each peptide epitopes and contains a
lipid moiety that can be coupled to other amino acids without
modifying standard peptide synthesis procedures (21). Thus it
would be less expensive and easier to manufacture. The ability to
synthesize lipopeptides in a highly pure, well-characterized state
quickly and cheaply makes them desirable for use in human [26].
A shift from standard parenteral administration to the needle-free,
non-invasive intranasal administration conferred by lipopeptides is
also advantageous from a logistical, economic, and safety
viewpoint [19,22,27].
The current paper described a rational approach to lipopeptide
vaccine design by optimizing the alkyl chain length of the lipid
moiety and position of the vaccine components for immunoge-
nicity following intranasal administration. Immunological assess-
ment of the lipopeptides identified a potential GAS vaccine
candidate with the capacity to elicit high titers of systemic IgG
which overcomes problems currently associated with the develop-
ment of a vaccine against GAS. Overall, this work provided a
rational basis for development of immunogenic lipopeptide
vaccines for the prevention or treatment of many diseases and is
of particular relevance to peptide based vaccines.
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